Affiliation:
1. First Department of Pathology, The National and Kapodistrian University of Athens, Medical School, Athens,Greece
2. Department of Food Science and Nutrition, University of the Aegean, Lemnos,Greece
Abstract
:
ELAV-like protein 1 or HuR (human antigen R) is an RNA-binding protein that in humans is
encoded by the ELAVL1 gene, and one of its best functions is to stabilize mRNAs in order to regulate
gene expression. HuR protein overexpression has undoubtedly been linked to an increased risk of tumor
growth, progression and metastasis, rendering it a potential therapeutic target candidate in cancer.
Novel agents, interfering with HuR expression, have been tested, both in vitro and in vivo, with promising
results. The aim of this paper is to review the existing literature regarding the potential agents that
could actively act on and inhibit HuR expression. HuR molecule controls the expression of various
proto-oncogenes, cytokines and growth factors, representing a major player in tumor progression, invasion
and metastasis and constituting an emerging target for cancer therapy. PubMed database was thoroughly
searched, and all published articles providing scientific data on molecules that can exhibit antitumorigenic
effects via HuR inhibition were included. According to these data, HuR inhibition should
be a promising target in cancer therapeutics.
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmacology,Molecular Medicine,Drug Discovery,Biochemistry,Organic Chemistry
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献